Abstract
Pulmonary hypertension (PHT) encompasses a set of diseases with distinct etiologies that have the presence of a high mean pulmonary arterial pressure (mPAP) in common. It is classified into 5 groups, with PHT due to left cardiopathy, or group 2, being the most prevalent. At present, most targeted therapies are only approved for the treatment of group 1 hypertension or pulmonary arterial hypertension (PAH) (both in monotherapy and combination therapy). Risk stratification being the best tool for evaluating treatment response. The main prognostic factor is the degree of right ventricular dysfunction. The treatment of PHT secondary to pulmonary disease consists of optimizing management of the underlying pathology. A pulmonary thromboendarterectomy is the treatment of choice for chronic thromboembolic PHT. When faced with an inadequate treatment response, early referral to a transplantation center should be considered.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
